Clinical trials: Progressive Multiple Sclerosis
Multiple Sclerosis, Myasthenia Gravis
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or…
- Trial name
- NCT06220201
- Testing
- CC-97540, Fludarabine, Cyclophosphamide
- Where
- 34 sites in United States, Belgium and 4 more
- Volunteers
- 120 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Progressive Multiple Sclerosis
Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis
The purpose of this study is to determine whether cyclic oral methylprednisolone once every month has an effect on the intrathecal inflammation in patients suffering from progressive multiple sclerosis.
- Trial name
- COMTiMS (NCT01305837)
- Testing
- methylprednisolone
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Multiple Sclerosis, Progressive Multiple Sclerosis
Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis
The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis.
- Trial name
- Norseman (NCT05740722)
- Testing
- Nicotinamid riboside
- Where
- Norway
- Volunteers
- 300 people
- Sponsor
- Haukeland University Hospital
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies
This was an observational retrospective cohort study using electronic medical records (EMRs) to study immunoglobulin levels over time among patients with relapsing forms of multiple sclerosis (MS) newly initiating anti-CD20…
- Conditions
- Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06526000
- Where
- United States
- Volunteers
- 326 people
- Sponsor
- Novartis
Primary Progressive Multiple Sclerosis
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
The goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.
- Trial name
- ORATORIO-CP (NCT05974852)
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 732 people
- Sponsor
- State University of New York at Buffalo
Multiple Sclerosis
Rehabilitative Protocols in Progressive Multiple Sclerosis Treated with Anti CD20 Monoclonal Antibodies
Progressive multiple sclerosis (MS) patients have usually a worsening clinical course and it remains unclear if rehabilitation can indeed slow down the progression of the disease.
- Trial name
- Reup (NCT06894940)
- Testing
- Active Comparator #1, Experimental
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- University of Pavia
Multiple Sclerosis, Primary Progressive
Cognition Evolution and MRI Markers in PPMS Patients on 2 Years
Cognitive impairment is nowadays more and more recognized as an important feature of the multiple sclerosis (MS) disease. Cognitive disorders frequency in MS is estimated between 40 and 60%.
- Trial name
- PRO-COG (NCT03455582)
- Testing
- Clinical assessment, Ecological evaluation, Neuropsychological evaluation
- Where
- 3 sites in France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Multiple Sclerosis, Progressive
The Effect of High Intensity Interval Training on Cardiovascular Fitness in People With Progressive Multiple Sclerosis.
This is a pilot trial to explore the cardiovascular of eight weeks of twice weekly high intensity interval training in people with progressive multiple sclerosis.
- Trial name
- NCT02950454
- Testing
- High intensity interval training, Continuous moderate exercise
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Glasgow
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints.
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- RemiSeven (NCT07222956)
- Testing
- Remibrutinib (Open Label)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Moein Amin
Multiple Sclerosis
Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS
This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.
- Trial name
- NCT07535242
- Volunteers
- 22 people
- Sponsor
- Ondokuz Mayıs University
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Primary Progressive
The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients
Abstract Introduction: Postural control disorders are the most common motor disorder associated with multiple sclerosis. Objective: The aim of this study is to demonstrate the potential for improvement of postural control, motion…
- Trial name
- NCT03424538
- Testing
- Neurorehabilitation, Physiotherapy
- Where
- Hungary
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Somogy Megyei Kaposi Mór Teaching Hospital
Multiple Sclerosis
Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity
Aim of this randomized, double-blind, placebo-controlled, cross-over study is to investigate cannabinoid-induced changes in neurophysiological parameters in a group of 40 patients with secondary or primary progressive Multiple…
- Trial name
- NS-MSS (NCT01538225)
- Testing
- Sativex®
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Almirall, S.A.
Multiple Sclerosis, Chronic Progressive
Evidence Based Patient Information and Smartphone Accelerometry to Enhance Physical Activity in MS
Due to their ubiquitary distribution, smartphones might serve as an easy way/ possibility to use feedback mechanism in an app-based intervention program to increase physical activity in Multiple Sclerosis (MS) patients.
- Trial name
- PIA (NCT03114293)
- Testing
- Smartphone App
- Volunteers
- 40 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF).
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS
- Trial name
- NCT06683612
- Testing
- PIPE-791
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
Secondary Progressive Multiple Sclerosis
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
This is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of the placebo-controlled period (Part 1), participants will have the option of enrolling in a 2-year open-label extension (Part 2).
- Trial name
- ASCEND in SPMS (NCT01416181)
- Testing
- natalizumab
- Where
- 161 sites in United States, Belgium and 15 more
- Volunteers
- 889 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple Sclerosis
Little is known about the potential effects of exercise on the underlying disease mechanisms in multiple sclerosis (MS). Although contactin-1 and contactin-2 are known as two proteins involved in axonal regeneration, it is…
- Trial name
- NCT05351411
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Firat University
Primary Progressive Multiple Sclerosis
This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.
The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS.
- Trial name
- INFORMS (NCT00731692)
- Testing
- FTY720
- Where
- 157 sites in United States, Australia and 16 more
- Volunteers
- 970 people
- Sponsor
- Novartis Pharmaceuticals
Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS)
Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis.
The goal of this clinical trial is to learn if an online wellness program can lower fatigue and improve mood and quality of life in people with progressive multiple sclerosis who are 45 to 70 years old and are experiencing…
- Trial name
- DEW (NCT07831928)
- Testing
- Online wellness course and online exercise platform, Usual Care Group
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- University of Iowa
Multiple Sclerosis, Chronic Progressive
Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
The purpose of the study is to determine if lipoic acid can protect the brain and slow disability in secondary progressive multiple sclerosis.
- Trial name
- NCT01188811
- Testing
- lipoic acid
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
Safety Study of GNbAC1 in Multiple Sclerosis Patients
The purpose of this study is to assess the safety and tolerability of single ascending doses, as well as of repeated administrations of GNbAC1 in MS patients.
- Trial name
- NCT01639300
- Testing
- GNbAC1
- Where
- 2 sites in Switzerland
- Volunteers
- 10 people
- Sponsor
- GeNeuro Innovation SAS